The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study.
A prospective study was carried out in 25 patients with systemic lupus erythematosis (SLE) on the effect of normalizing serum complement (CH50) and anti-DNA antibodies on the course of lupus nephritis. In 16 of the 25 patients, CH50 was maintained within the normal range for two years. Urinary protein excretion increased or remained low in all 16. Repeat renal biopsies were performed in 10 of these 16, and disclosed either stabilization of glomerular disease or diminution. In the nine patients in whom CH50 could not be normalized with tolerated doses of drugs, urinary protein excretion increased or remained increased. Repeat renal biopsies in six of these nine patients were carried out and showed worsening of glomerular disease in five. No clear-cut correlation was found between urinary protein excretion or renal disease and the serum levels of anti-DNA antibody. We conclude from these observations that continuous normalization of CH50 by drug therapy in patients with SLE is associated with stabilization or diminution of lupus nephritis.
D000906:Antibodies / Q000032:analysis; D001379:Azathioprine / Q000627:therapeutic use; D003165:Complement System Proteins / Q000032:analysis; D004247:DNA / Q000276:immunology*; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000652:urine; D009393:Nephritis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000652:urine; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D011507:Proteinuria
D000906:Antibodies; D003165:Complement System Proteins; D004247:DNA; D001379:Azathioprine; D011241:Prednisone